Literature DB >> 26001263

MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors.

Feng Hua Ma1, Jin Wei Qiang, Song Qi Cai, Shu Hui Zhao, Guo Fu Zhang, Ya Min Rao.   

Abstract

OBJECTIVE: The purpose of this article is to investigate the proton MR spectroscopy ((1)H-MRS) features of solid adnexal tumors and to evaluate the efficacy of (1)H-MRS for differentiating benign from malignant solid adnexal tumors.
MATERIALS AND METHODS: Sixty-nine patients with surgically and histologically proven solid adnexal tumors (27 benign and 42 malignant) underwent conventional MRI and (1)H-MRS. Single-voxel spectroscopy was performed using the point-resolved spectroscopy localization technique with a voxel size of 2 × 2 × 2 cm(3). Resonance peak integrals of choline, N-acetyl aspartate (NAA), creatine, lactate, and lipid were analyzed, and the choline-tocreatine, NAA-to-creatine, lactate-to-creatine, and lipid-to-creatine ratios were recorded and compared between benign and malignant tumors.
RESULTS: A choline peak was detected in all 69 cases (100%), NAA peak in 67 cases (97%, 25 benign and 42 malignant), lipid peak in 47 cases (17 benign and 30 malignant), and lactate peak in eight cases (four benign and four malignant). The mean (± SD) choline-tocreatine ratio was 5.13 ± 0.6 in benign tumors versus 8.90 ± 0.5 in malignant solid adnexal tumors, a statistically significant difference (p = 0.000). There were no statistically significant differences between benign and malignant tumors in the NAA-to-creatine and lipid-to-creatine ratios (p = 0.263 and 0.120, respectively). When the choline-to-creatine threshold was 7.46 for differentiating between benign and malignant tumors, the sensitivity, specificity, and accuracy were 94.1%, 97.1%, and 91.2%, respectively.
CONCLUSION: Our preliminary study shows that the (1)H-MRS patterns of benign and malignant solid adnexal tumors differ. The choline-to-creatine ratio can help clinicians differentiate benign from malignant tumors.

Entities:  

Keywords:  MRI; adnexal tumors; ovarian tumors; spectroscopy

Mesh:

Substances:

Year:  2015        PMID: 26001263     DOI: 10.2214/AJR.14.13391

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  Proton MR spectroscopy and the detection of malignancy in ovarian masses.

Authors:  Sahar Mahmoud Mansour; Mohammed Mohammed Mohammed Gomma; Peter Nashaat Shafik
Journal:  Br J Radiol       Date:  2019-07-18       Impact factor: 3.039

Review 2.  In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.

Authors:  Rossella Canese; Delia Mezzanzanica; Marina Bagnoli; Stefano Indraccolo; Silvana Canevari; Franca Podo; Egidio Iorio
Journal:  Front Oncol       Date:  2016-06-28       Impact factor: 6.244

3.  In vivo detection of dysregulated choline metabolism in paclitaxel-resistant ovarian cancers with proton magnetic resonance spectroscopy.

Authors:  Jing Lu; Ying Li; Yong Ai Li; Li Wang; An Rong Zeng; Xiao Liang Ma; Jin Wei Qiang
Journal:  J Transl Med       Date:  2022-02-15       Impact factor: 5.531

4.  The contribution of the 1H-MRS lipid signal to cervical cancer prognosis: a preliminary study.

Authors:  Miriam Dolciami; Rossella Canese; Claudia Testa; Angelina Pernazza; Giusi Santangelo; Innocenza Palaia; Carlo Della Rocca; Carlo Catalano; Lucia Manganaro
Journal:  Eur Radiol Exp       Date:  2022-10-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.